These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 12656907)
21. Effects of long term sildenafil on the acute phase of Peyronie's disease in a combination treatment. Topcuoglu M; Çakan M Arch Ital Urol Androl; 2022 Sep; 94(3):319-322. PubMed ID: 36165478 [TBL] [Abstract][Full Text] [Related]
22. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Rehman J; Benet A; Melman A Urology; 1998 Apr; 51(4):620-6. PubMed ID: 9586617 [TBL] [Abstract][Full Text] [Related]
23. Effectiveness of antioxidants (propolis, blueberry, vitamin E) associated with verapamil in the medical management of Peyronie's disease: a study of 151 cases. Paulis G; D'Ascenzo R; Nupieri P; De Giorgio G; Orsolini G; Brancato T; Alvaro R Int J Androl; 2012 Aug; 35(4):521-7. PubMed ID: 21950543 [TBL] [Abstract][Full Text] [Related]
24. Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie's disease: a phase I study. Pavone C; Napoli G; Caruana G; Alonge V; Usala M; Abbadessa D BJU Int; 2012 Jul; 110(1):117-21. PubMed ID: 22176734 [TBL] [Abstract][Full Text] [Related]
25. Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial. Greenfield JM; Shah SJ; Levine LA J Urol; 2007 Mar; 177(3):972-5. PubMed ID: 17296390 [TBL] [Abstract][Full Text] [Related]
26. Systemic corticosteroid treatment in Peyronie's disease. Uzun H Med Hypotheses; 2013 Dec; 81(6):1029-30. PubMed ID: 24119766 [TBL] [Abstract][Full Text] [Related]
27. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. Hellstrom WJ; Kendirci M; Matern R; Cockerham Y; Myers L; Sikka SC; Venable D; Honig S; McCullough A; Hakim LS; Nehra A; Templeton LE; Pryor JL J Urol; 2006 Jul; 176(1):394-8. PubMed ID: 16753449 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of Collagenase Clostridium histolyticum (Xiapex Cocci A; Di Maida F; Russo GI; Capogrosso P; Francesco L; Rizzo M; Di Mauro M; Salonia A; Cito G; Falcone M; Romano A; Polloni G; Martinez-Salamanca JI; Fernández-Pascual E; Minervini A; Mondaini N Clin Drug Investig; 2020 Jun; 40(6):583-588. PubMed ID: 32342279 [TBL] [Abstract][Full Text] [Related]
38. Peyronie's disease in men under age 40: characteristics and outcome. Tefekli A; Kandirali E; Erol H; Alp T; Köksal T; Kadioğlu A Int J Impot Res; 2001 Feb; 13(1):18-23. PubMed ID: 11313836 [TBL] [Abstract][Full Text] [Related]
39. Intralesional hyaluronic acid: an innovative treatment for Peyronie's disease. Gennaro R; Barletta D; Paulis G Int Urol Nephrol; 2015 Oct; 47(10):1595-602. PubMed ID: 26257044 [TBL] [Abstract][Full Text] [Related]
40. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. Palmieri A; Imbimbo C; Creta M; Verze P; Fusco F; Mirone V Int J Androl; 2012 Apr; 35(2):190-5. PubMed ID: 22085227 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]